Ion-dependent slow protein release from in vivo disintegrating micro-granules

Drug Deliv. 2021 Dec;28(1):2383-2391. doi: 10.1080/10717544.2021.1998249.

Abstract

Through the controlled addition of divalent cations, polyhistidine-tagged proteins can be clustered in form of chemically pure and mechanically stable micron-scale particles. Under physiological conditions, these materials act as self-disintegrating protein depots for the progressive release of the forming polypeptide, with potential applications in protein drug delivery, diagnosis, or theragnosis. Here we have explored the in vivo disintegration pattern of a set of such depots, upon subcutaneous administration in mice. These microparticles were fabricated with cationic forms of either Zn, Ca, Mg, or Mn, which abound in the mammalian body. By using a CXCR4-targeted fluorescent protein as a reporter building block we categorized those cations regarding their ability to persist in the administration site and to sustain a slow release of functional protein. Ca2+ and specially Zn2+ have been observed as particularly good promoters of time-prolonged protein leakage. The released polypeptides result is available for selective molecular interactions, such as specific fluorescent labeling of tumor tissues, in which the protein reaches nearly steady levels.

Keywords: Protein materials; microparticles; protein depots; self-disintegrating materials; tumor targeting.

MeSH terms

  • Administration, Oral
  • Animals
  • Cations, Divalent / chemistry*
  • Chemistry, Pharmaceutical
  • Dose-Response Relationship, Drug
  • Drug Carriers / chemistry
  • Drug Liberation
  • Female
  • Histidine / chemistry*
  • Injections, Subcutaneous
  • Mice
  • Nanoparticles / chemistry*
  • Particle Size
  • Proteins / administration & dosage*
  • Proteins / pharmacokinetics
  • Receptors, CXCR4 / metabolism
  • Xenograft Model Antitumor Assays

Substances

  • Cations, Divalent
  • Drug Carriers
  • Proteins
  • Receptors, CXCR4
  • polyhistidine
  • Histidine

Grants and funding

We are indebted to AGAUR (INVITA, grant 2020PANDE00003), AGAUR (2017SGR-229) and CIBER-BBN (projects NANOPROTHER) granted to A.V. E.V. received support from AEI (PID2019-105416RB-I00/AEI/10.13039/501100011033) and CIBER-BBN (project NANOREMOTE). R.M. received support from ISCIII-AEI (PI18/00650, co-funding FEDER), CIBER-BBN (4NanoMets project), and AGAUR (2017 SGR 865 GRC). U.U. was supported by Miguel Servet contract (CP19/00028) from ISCIII co-funded by European Social Fund (ESF investing in your future) and H.L.L. by a predoctoral fellowship from AGAUR (2019FI_B00352). E.V.D. was supported by a predoctoral fellowship from Ministerio de Ciencia, Innovación y Universidades (FPU18/04615). A.V. received an ICREA ACADEMIA award. U.U received support from ISCIII-AEI (PI20/00400) co-funded by FEDER ( a way to make Europe) and Miguel Servet contract (CP19/00028) from ISCIII co-funded by European Social Fund (ESF investing in your future).Protein production was partially performed by the ICTS ‘NANBIOSIS,’ more specifically by the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN)/IBB, at the UAB (http://www.nanbiosis.es/portfolio/u1-protein-production-platform-ppp/). The in vivo work was performed by the ICTS NANBIOSIS of the CIBER-BBN Nanotoxicology Unit (http://www.nanbiosis.es/portfolio/u18-nanotoxicology-unit/).